Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,400
- 试验地点
- 16
- 主要终点
- Incidence of adverse events
研究概览
简要总结
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
详细描述
This is a multicenter open-label extension study assessing long term safety and efficacy of SPN-812 (viloxazine extended-release capsules) in pediatric subjects with ADHD who completed a randomized, double-blind, placebo-controlled clinical trial, including (A) a Phase 2 (Study 812P202: children 6 to 12 years of age) or a Phase 3 trial (Study 812P301 or 812P303: children 6 to 11 years of age; or Study 812P302 or 812P304: adolescents 12 to 17 years of age) or (B) a Phase 4 trial (Study 812P401: preschool-age children, 4-5 years of age). The study is divided into two phases, Optimization and Maintenance phases. Subjects in Cohort 'A' who completed a Phase 2 or Phase 3 trial followed protocol Schedule 'A' (exposure up to 72 months). Subjects in Cohort 'B' who complete the Phase 4 trial will follow Schedule 'B' (exposure up to 6 months).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cohort 'A' Inclusion/
排除标准
- •Inclusion Criteria 'A':
- •Completion of a previous blinded study of SPN-812 for the treatment of ADHD.
- •Continues to be medically healthy and with clinically normal laboratory profiles, vital signs, and electrocardiograms (ECGs).
- •Weight of at least 20 kg if 6-11 years old and at least 35 kg if 12 years or older.
- •Written Informed Consent obtained from the subject's parent or legally authorized representative (LAR); and written Informed Assent obtained from the subject if appropriate; written Informed Consent obtained from the subject if he/she is 18 years old.
- •Females of Childbearing Potential (FOCP) must be either sexually inactive (abstinent) or, if sexually active, must agree to use one of the following acceptable birth control methods beginning 30 days prior to the first dose, throughout the study:
- •simultaneous use of male condom and intra-uterine contraceptive device placed at least four weeks prior to the first study drug administration
- •surgically sterile male partner
- •simultaneous use of male condom and diaphragm with spermicide
- •established hormonal contraceptive
- •Exclusion Criteria 'A':
- •Current diagnosis of significant systemic disease or of a major psychiatric or neurological disorder, including history or family history of seizures or seizure-like disorders. History of Major Depressive Disorder is allowed if the subject is free of episodes currently and for the last six months.
- •Current evidence of suicidal ideation and/or behaviors (assessed with Columbia Suicide Severity Rating Scale or C-SSRS).
- •Body Mass Index (BMI) greater than 95th percentile for the appropriate age and gender (according to the CDC BMI-for-Age Growth Charts for boys and girls).
- •Pregnancy, breastfeeding, or refusal to practice contraception during the study for female subjects of childbearing potential (FOCP).
- •Current substance or alcohol use.
- •Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
- •Cohort 'B' Inclusion/Exclusion Criteria:
- •Inclusion Criteria 'B':
- •Has completed a previous Study 812P401 and is less than 6 years of age at Visit 1 in this study (812P310).
- •Continues to be medically healthy with clinically normal laboratory profiles, vital signs, and electrocardiograms.
- •Weighs at least ≥5th percentile for age and sex.
- •Parent or LAR is willing and able to provide Written Informed Consent.
- •Exclusion Criteria 'B':
- •Has a current diagnosis of significant systemic disease and/or of a major psychiatric or neurological disorder.
- •Current evidence of suicidal ideation and/or behaviors (assessed with Columbia Suicide Severity Rating Scale or C-SSRS), is at significant risk of suicide, either in the opinion of the Investigator or defined as a "yes" to suicidal ideation C-SSRS questions 4 or 5 or answering "yes" to suicidal behavior on the C-SSRS at Visit 1 or has attempted suicide from day of end of study in previous blinded study to day of Visit 1 in this study (812P310).
- •Has a BMI >95th percentile for the appropriate age and sex (according to the CDC BMI-for-Age Growth Charts for boys and girls).
- •Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
研究组 & 干预措施
Open-Label Treatment
Cohort 'A': Children and adolescents, 6-17 years of age, who completed a Phase 2 (Study 812P202) or Phase 3 (Study 812P301, 812P302, 812P303, or 812P304) randomized, double-blind, placebo-controlled clinical trial.
Cohort 'B': Preschool-age children, 4-5 years of age, who completed a Phase 4 (Study 812P401) randomized, double-blind, placebo-controlled clinical trial.
干预措施: SPN-812 (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: up to 72 months
The incidence (percentage of subjects dosed) of adverse events by System Organ Class and Preferred term by cohort
次要结局
- Trends in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV-Preschool, ADHD-RS-IV or ADHD-RS-5) Score(up to 72 months)
- Trends in Clinical Global Impression-Improvement (CGI-I) scale score(up to 72 months)